Sandra Kurtin

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Mario E. Lacouture, Michael L. Maitland, Siegfried Segaert et al. · Supportive Care in Cancer · 2010 · 148 citations

Medicine, Toxicity Study Group, Pathology +10

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer

Tomislav Dragovich, David S. Mendelson, Sandra Kurtin et al. · Cancer Chemotherapy and Pharmacology · 2006 · 137 citations

Medicine, Colorectal Cancer, Pathology +4

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

Daruka Mahadevan, Ruth Plummer, Matthew Squires et al. · Annals of Oncology · 2011 · 86 citations · Full text

Pharmacodynamic Study, Oncology, Medicine +7

Myeloid Toxicity of Cancer Treatment

Sandra Kurtin · Journal of the Advanced Practitioner in Oncology · 2012 · 59 citations · Full text

Hematological Malignancy, Oncology, Bone Marrow Failure +15

The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center

Mohanad Al‐Obaidi, Ahmet B. Gungor, Sandra Kurtin et al. · The American Journal of Medicine · 2022 · 47 citations · Full text

Vaccination, Preventive Medicine, Large Academic Center +9